- CVS Caremark to stop selling tobacco in all store locations
- FTC grants early termination of waiting period for Kroger, Harris Teeter deal
- Walgreens expanding scope of retail pharmacy experience and services heading into fiscal 2014
- Family Dollar elevates Jason Reiser to chief merchandising officer; president and COO Michael Bloom departs
- Walmart expanding small store fleet based on fresh- and pharmacy-driven growth
WESTLAKE VILLAGE, Calif. — Dole Food Company, Inc., and David H. Murdock, Dole’s chairman and CEO, today jointly announced that they have signed a definitive merger agreement pursuant to which Murdock, acting through his affiliates, will acquire for cash all of the outstanding shares of Dole common stock not currently beneficially held by him.
Under the terms of the merger agreement, Dole stockholders will receive $13.50 in cash for each share of Dole common stock that they hold, in a transaction which (with the assumption of debt) places the total enterprise value of Dole at approximately $1.6 billion. This price represents an increase of $1.50 per share from the original proposal Murdock delivered to Dole on June 10, 2013, and a premium of 32% over the $10.20 per share price of the stock immediately prior to such proposal.
The board of directors of Dole, with Mr. Murdock abstaining, acting on the unanimous recommendation of a special committee of independent and disinterested directors, unanimously approved the merger agreement pursuant to which Murdock will take the company private. The transaction is subject to a number of conditions, including approval by at least a majority of the outstanding shares of common stock held by stockholders of Dole other than Murdock and his affiliates. The special committee was formed after Murdock delivered the original proposal to Dole.
The transaction will be financed through a combination of cash and equity contributed by Mr. Murdock, as well as financing that has been committed by Deutsche Bank, Bank of America and The Bank of Nova Scotia. The transaction is subject to other customary conditions, including receipt of required regulatory approvals, in addition to the stockholder approval mentioned above. The merger agreement provides for a “go-shop” period of 30 days, during which the special committee, with the assistance of Lazard, will actively solicit, receive, evaluate and potentially enter into negotiations with parties that offer alternative proposals. The transaction is expected to close during the fourth quarter of 2013.
Lazard acted as financial advisor to the special committee. Mr. Murdock was advised by Deutsche Bank Securities Inc. in connection with the transaction.
For further information regarding the terms and conditions of the proposed merger, please see Dole’s Current Report on Form 8-K filed today with the SEC.
Like this story? Find us on Facebook for more insight, analysis and the latest in drug store news. Join the conversation.